Clinical Trials on Postpericardiotomy Syndrome

Total 33926 results

H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Myelodysplastic Syndromes

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Duke University
Celgene Corporation

Completed

Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States, Canada
Seoul National University Hospital

Completed

Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome (H-1012-015-342)

Myelodysplastic Syndromes

Korea, Republic of
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Myelodysplastic Syndromes

Italy
Basque Health Service

Unknown

Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

Myelodysplastic Syndrome

Spain
Cooperative Study Group A for Hematology

Unknown

Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (RICandDLI)

Myelodysplastic Syndrome

Korea, Republic of
Amgen

Completed

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
Tel-Aviv Sourasky Medical Center

Unknown

Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) (IMDS001)

Myelodysplastic Syndrome

Israel
Groupe Francophone des Myelodysplasies

Unknown

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Myelodysplastic Syndromes

France
Novacea

Unknown

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
Centre Hospitalier Universitaire de Besancon

Unknown

Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study (SCANAPIV)

Intra-Abdominal Hypertension | Abdominal Compartment Syndrome
Marathon Pharmaceuticals, LLC

Withdrawn

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

Short Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short Bowel

United States
National Institutes of Health Clinical Center (CC)

Completed

Leucovorin for the Treatment of 5 q Minus Syndrome

Myelodysplastic Syndrome | 5q Minus Syndrome

United States
Jazz Pharmaceuticals

Recruiting

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Tuberous Sclerosis Complex | Dravet Syndrome | Lennox Gastaut Syndrome

United States
Minovia Therapeutics Ltd.

Recruiting

Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Israel
M.D. Anderson Cancer Center

Recruiting

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Anhui Provincial Hospital

Recruiting

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Myelodysplastic Syndromes

China
GWT-TUD GmbH
Celgene

Recruiting

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. (LUSPLUS)

Myelodysplastic Syndromes

Austria, Germany, Spain, Switzerland
Akeso

Recruiting

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

China
University Hospital, Toulouse

Recruiting

Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes (IMET-MDS)

Myelodysplastic Syndromes

France
Peking University People's Hospital

Recruiting

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Myelodysplastic Syndromes

China
Institut Paoli-Calmettes

Recruiting

Institut Paoli Calmettes Myelodysplastic Syndromes Database

Myelodysplastic Syndromes

France
Yonsei University

Recruiting

Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
Washington University School of Medicine
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Fundación General de la Universidad de Salamanca
Celgene Corporation

Completed

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

Myelodysplastic Syndrome

Germany, Spain, France
Sumitomo Pharma Co., Ltd.

Completed

Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Columbia University; Karyopharm Therapeutics Inc

Completed

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
Montefiore Medical Center
Albert Einstein College of Medicine

Withdrawn

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Boehringer Ingelheim

Terminated

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Germany
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
PersImmune, Inc
University of California, San Diego

Unknown

Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

Myelodysplastic Syndromes

United States
Celgene

Completed

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
GlaxoSmithKline
Parexel

Terminated

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndrome

United States, Spain
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States

Clinical Trials on Postpericardiotomy Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations